12 Healthcare Stocks Move in Friday's After-Market Session
ByAinvest
Friday, Sep 12, 2025 10:04 pm ET1min read
ADAP--
These fluctuations underscore the volatile nature of the healthcare sector, where stocks can experience substantial price changes in response to various factors such as clinical trial results, regulatory approvals, and market sentiment. Investors should closely monitor these developments to make informed investment decisions.
BIAF--
CHEK--
GCTK--
Check-Cap CHEK shares increased by 111.7% to $1.57, while bioAffinity Technologies BIAF stock rose by 23.79% to $0.34. Adaptimmune Therapeutics ADAP shares increased by 9.82% to $0.06 and GlucoTrack GCTK stock moved upwards by 9.51% to $11.51. Losers included Kalaris Therapeutics KLRS stock, which fell 7.0% to $3.62, and China SXT Pharmaceuticals SXTC shares, which declined by 5.53% to $1.88.
In the healthcare sector, several stocks experienced significant movements during Friday's after-market session. Check-Cap (CHEK) shares surged by an impressive 111.7%, reaching $1.57, while bioAffinity Technologies (BIAF) stock rose by 23.79% to $0.34. Adaptimmune Therapeutics (ADAP) shares increased by 9.82% to $0.06, and GlucoTrack (GCTK) stock moved upwards by 9.51% to $11.51. Meanwhile, Kalaris Therapeutics (KLRS) stock fell by 7.0% to $3.62, and China SXT Pharmaceuticals (SXTC) shares declined by 5.53% to $1.88 [2].These fluctuations underscore the volatile nature of the healthcare sector, where stocks can experience substantial price changes in response to various factors such as clinical trial results, regulatory approvals, and market sentiment. Investors should closely monitor these developments to make informed investment decisions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet